See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Natural Disasters
Democratic Party
Republican Party
Social Media
US Politics
Tariffs
Education
Eid
Artificial Intelligence
Donald Trump
Baseball
Senate
Published • loading... • Updated

First Three Children to Commence Treatment With Ryoncil® - Mesoblast (NASDAQ:MESO)

Summary by Benzinga
NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid National Drug Rebate Agreement (NDRA) with the U.S. Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services, for Ryoncil® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food…

3 Articles

All
Left
Center
1
Right
BenzingaBenzinga
Center

First Three Children to Commence Treatment With Ryoncil® - Mesoblast (NASDAQ:MESO)

NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid National Drug Rebate Agreement (NDRA) with the U.S. Centers for Medicare & Medicaid Services (CMS), Department of Health and Human Services, for Ryoncil® (remestemcel-L), the first mesenchymal stromal cell (MSC) therapy approved by U.S. Food…

·New York, United States
Read Full Article
themarketonline.com.authemarketonline.com.au

Mesoblast kicks off treatment for first 3 kids with graft-host disease. So why are shares down?

HotCopper favourite Mesoblast (ASX:MSB) has begun treating the first three children with skin graft-versus-host disease in the U.S., at the same time the company received Medicare (U.S.) and Medicaid coverage. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more. That coverage, under the way it works in the States, now means – quoting Mesoblast – …

Read Full Article
sharecafe.com.ausharecafe.com.au

Mesoblast's Ryoncil Receives US Medicaid Coverage

Mesoblast (MSB:ASX; MESO:Nasdaq) has secured a significant agreement with the U.S. Centers for Medicare & Medicaid Services (CMS) for its Ryoncil (remestemcel-L) therapy. The Medicaid National Drug Rebate Agreement (NDRA) ensures both inpatient and outpatient access to Ryoncil for approximately 40% of U.S. children covered by Medicaid who suffer from steroid-refractory acute graft versus host disease (SR-aGvHD). This agreement, effective July 1,…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Sunday, March 30, 2025.
Sources are mostly out of (0)

Similar News Topics

Stock Markets

Stock Markets

Medicare

Medicare

Medical

Medical

United States

United States

US Economy

US Economy

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal